Exhibit 99.1
Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development
Officer
- Cell therapy and oncology drug development expert aims to lead Senti Bios novel off-the-shelf CAR-NK cell oncology programs into and through clinical development -
SOUTH SAN FRANCISCO, Calif., May 25, 2022 Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today
announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer. Dr. Rajangam, who will join the company this July, is an experienced biotechnology executive with an extensive track record of successfully
developing cancer therapies across multiple modalities.
Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits,
which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Senti Bios oncology pipeline uses healthy adult donor-derived, natural killer (NK) cells
engineered with chimeric antigen receptor (CAR) gene circuits that are cryopreserved and dosed off-the-shelf.
We have made tremendous progress over the last year in advancing multiple oncology programs toward the clinic. Looking forward, as we aim to transition
from a platform company to a clinical-stage biotech, we are honored to welcome such a highly-successful drug developer to our leadership teamKanya is uniquely suited to help Senti Bio navigate this transition and advance our off-the-shelf CAR-NK cell pipeline while creating additional gene circuit-enabled programs, said Timothy Lu, MD, PhD, Chief
Executive Officer and Co-Founder of Senti Bio. Kanyas experience spans early- to late-stage biotech companies, including gaining product approvals in both liquid and solid tumors, and leading CAR-NK cell therapy programs through the IND process and rapidly demonstrating clinical proof-of-concept.
This is an extremely exciting time as Senti Bio aims to ramp up late-preclinical and early-clinical development activities to support off-the-shelf CAR-NK cell product candidates, SENTI-202 and
SENTI-301, toward anticipated INDs next year, said Dr. Rajangam. Senti Bios use of Logic Gated gene circuits in its
off-the-shelf CAR-NK designs has the potential to selectively target tumors while sparing healthy cells and, I believe, expand
the cell therapy opportunity to additional tumor types including acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer and others. I am also drawn to the broad potential of the companys proprietary gene circuit platform to create
smarter medicines against a diverse set of therapeutic areas. I am looking forward to joining Senti Bios fun and energetic culture while continuing to have a meaningful impact on the lives of cancer patients.
As Chief Medical and Development Officer, Dr. Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance
Senti Bios off-the-shelf CAR-NK cell oncology programs into and through clinical development. Dr. Rajangam joins Senti Bio
from Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology. Prior to Nkarta, she was chief medical officer at Atara
Biotherapeutics where she led the development of T-cell therapies for oncology, neurology and infectious diseases. Prior to that, Dr. Rajangam was chief medical officer of Cleave Biosciences, where she led
oncology clinical development programs. Prior to becoming a chief medical officer, Dr. Rajangam gained relevant senior leadership experience at Onyx and Exelixis, while contributing to the clinical development and global approval of several
marketed oncology products including Kyprolis®, Cotellic® and
Cometriq®/Cabometyx®. Dr. Rajangam received a medical degree from St. Johns Medical College and completed her surgical
residency with a focus on oncology at the Postgraduate Institute of Medical Education and Research (PGIMER), both in India. She received a PhD in biomedical cell and tissue engineering from Northwestern University. Dr. Rajangam serves on the
board of directors of Turnstone Biologics, a clinical-stage biotechnology company developing next-generation tumor infiltrating lymphocyte cell therapies and oncolytic virus cancer immunotherapies.